Beam Therapeutics Inc (NASDAQ:BEAM) price on Thursday, May 01, fall -0.50% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $19.83.
A look at the stock’s price movement, the close in the last trading session was $19.93, moving within a range at $19.31 and $20.575. The beta value (5-Year monthly) was 2.019. Turning to its 52-week performance, $35.25 and $13.52 were the 52-week high and 52-week low respectively. Overall, BEAM moved 12.45% over the past month.
Beam Therapeutics Inc’s market cap currently stands at around $1.99 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-24.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BEAM is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 4 recommend BEAM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BEAM’s current price about 12.63% and -10.35% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.44, while 7-day volatility ratio is 4.94% and 9.34% in the 30-day chart. Further, Beam Therapeutics Inc (BEAM) has a beta value of 2.35, and an average true range (ATR) of 1.55. Analysts have given the company’s stock an average 52-week price target of $38, forecast between a low of $25 and high of $57. Looking at the price targets, the low is -26.07% off current price level while to achieve the yearly target high, price needs to move -187.44%. Nonetheless, investors will most likely welcome a -91.63% jump to $38 which is the analysts’ median price.
If we refocus on Beam Therapeutics Inc (NASDAQ:BEAM), historical trading data shows that trading volumes averaged 1.8 over the past 10 days and 2.22 million over the past 3 months. The company’s latest data on shares outstanding shows there are 100.56 million shares.
The 14.51% of Beam Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 73.69% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 18.83 million on 2025-04-15, giving us a short ratio of 6.54. The data shows that as of 2025-04-15 short interest in Beam Therapeutics Inc (BEAM) stood at 2105.9999 of shares outstanding, with shares short rising to 12.16 million registered in 2025-03-14. Current price change has pushed the stock -20.04% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BEAM stock continues to rise going into the next quarter.
